evo视讯官网

Be the most trusted biotech company

2026-07-06

Henlius’ Serplulimab Final Analysis in nsqNSCLC Published in Cancer Communications, Reinforcing Durable Survival Benefit
2026-07-03

Lotus Pharmaceutical and Henlius Announce MFDS Approval of SERPLUMA® (serplulimab) for First-Line Treatment of ES-SCLC
2026-07-02

HETRONIFLY® (SERPLULIMAB) FORMALLY ENTERS ROUTINE USE IN THE NHS FOLLOWING NICE RECOMMENDATION, BECOMING THE FIRST ANTI-PD-1 IMMUNOTHERAPY FOR EXTENSIVE-STAGE SMALL CELL LUNG CANCER IN ENGLAND and WALES
2026-06-30

Henlius Doses First Patient with c-MET x EGFR Bispecific ADC HLX48
2026-06-29

Henlius Marks Eighth Consecutive Appearance at BIO 2026, Expanding Global Opportunities for Innovation
2026-06-26

Henlius’ Serplulimab Receives European Approval for a Fourth Indication, Expanding Its First-Line Treatment Footprint in Major High-Burden Cancers
2026-06-25

Henlius’ Proposed Ipilimumab Biosimilar HLX13 Completes First Patient Dosing in the U.S., Advancing Global Multicenter Clinical Development
2026-06-24

Organon CANADA and henlius Expand Access to Denosumab Treatments With LAUNCH OF BILDYOS® (Denosumab Injection) and TUZEMTY® (Denosumab Injection), Biosimilars to PROLIA and XGEVA
2026-06-23

Henlius’ Serplulimab Marks Third Publication in a Leading International Journal, with Small Cell Lung Cancer Long-Term Survival Data Published in JAMA Oncology and a 4-Year OS Rate of 21.9%